MedTrace Logo

Methotrexate for Central Serous Chorioretinopathy Treatment Trial

NCT01633983 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-07-20

No results posted yet for this study

Summary

Central serous chorioretinopathy (CSC) is a disease of unknown origin however multiple reports have indicated correlation of appearance of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may be beneficial in reducing this level thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. The investigators are going to try an escalating doses of MTX to treat CSC under full medical supervision.

Conditions

  • Central Serous Chorioretinopathy

Interventions

DRUG

Methotrexate

7.5 mg per week p.o. escalating up to 15 mg per week

DRUG

Delayed treatment

Methotrexate 7.5 mg per week per os escalating to 15 mg per week

Sponsors & Collaborators

  • Edward Averbukh

    lead OTHER

Principal Investigators

  • Edward Averbukh, MD · Hadassah Medical Organization

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2014-07-31
Completion
2015-07-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01633983 on ClinicalTrials.gov